厄贝沙坦治疗正常血压糖尿病肾病的临床观察

Clinical Observation of Irbesartan in the Treatment of Normal Blood Pressure Diabetic Nephropathy

目的观察短期应用厄贝沙坦片150 mg/d对不伴高血压的糖尿病肾病Ⅲ期患者血压及尿白蛋白/肌酐比值的影响。方法选择不伴高血压的糖尿病肾病Ⅲ期患者37例,待患者血糖控制平稳后,开始测定空腹血糖、血压及尿白蛋白/肌酐比值,同时开始给予所有患者厄贝沙坦片150 mg/d,服药2周后再次测定空腹血糖、血压及尿白蛋白/肌酐比值。结果治疗2周后,空腹血糖、收缩压、舒张压、尿白蛋白/肌酐比值的均值较治疗前均有降低,但差异无统计学意义(P> 0.05)。结论不伴高血压的糖尿病肾病Ⅲ期患者,在应用厄贝沙坦片150 mg/d治疗2周后,血压及尿白蛋白/肌酐比值的变化不明显。

Objective To observe the effects of two weeks use of irbesartan 150 mg/d on blood pressure and urine albumin/creatinine ratio in patients with diabetic nephropathy stage Ⅲ without hypertension. Methods 37 patients with diabetic nephropathy stage Ⅲ without hypertension were selected. After blood sugar control was stable, fasting blood sugar, blood pressure and urinary albumin/creatinine ratio were measured. At the same time, all patients were given irbesartan tablets 150 mg/d. Fasting blood sugar, blood pressure and urinary albumin/creatinine ratio were measured again after 2 weeks. Results After 2 weeks of treatment, the mean values of fasting blood sugar, systolic blood pressure, diastolic blood pressure and urinary albumin/creatinine ratio were lower than those before treatment, but there was no significant difference (P > 0.05). Conclusion For stage Ⅲ diabetic nephropathy patients without hypertension, the change of blood pressure and urine albumin/creatinine ratio was not obvious when irbesartan 150 mg/d was used for 2 weeks.